TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes

Liang Liu1,2, Weiying Zhou1,3, Chun-Ting Cheng4,5, Xiubao Ren2, George Somlo6, Miranda Y. Fong1, Andrew R. Chin1,5, Hui Li2, Yang Yu2, Yang Xu1, Sean Timothy Francis O'Connor1, Timothy R. O'Connor1, Manella Graduate School of Biological Sciences, Duarte, California. 2Department of Biotherapy and Key Laboratory of Cancer Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 3Department of Pharmacology, College of Pharmacy, The Third Military Medical University, Chongqing, China. 4Department of Molecular Pharmacology, City of Hope Beckman Research Institute and Medical Center, Duarte, California. 5Department of Medical Oncology, City of Hope Beckman Research Institute and Medical Center, Duarte, California. 6City of Hope Irell and Manella Graduate School of Biological Sciences, Duarte, California. Corresponding Author: S. Emily Wang, Department of Cancer Biology, Beckman Research Institute of City of Hope, 1500 East Duarte Road, KCRB Room 2007, Duarte, CA 91010. Phone: 626-256-4673, ext. 63118; Fax: 626-301-8972; E-mail: ewang@coh.org
doi: 10.1158/1541-7786.MCR-14-0201
©2014 American Association for Cancer Research.

Introduction

TGFβ proteins are multitasking cytokines involved in embryonic development, cell proliferation, motility and apoptosis, extracellular matrix production, and immunomodulation (1). In solid tumors, TGFβ can be produced by cancer and niche cells and acquires a cancer-promoting function. High TGFβ levels at tumor sites correlate with high histologic grade, risk of metastasis, and poor prognosis in patients with cancer (2). Previously, we reported that a gene-expression signature induced by TGFβ activation is associated with shorter patient survival in 295 primary breast cancers and is frequently found in tumors with a basal-like molecular profile (3). Those basal-like breast cancers are mostly sporadic but often share transcriptomic characteristics with tumors carrying BRCA1 germline mutations (4). They significantly overlap (80%) with triple-negative breast cancers (TNBC; negative for hormone receptors and HER2), exhibit high expression of DNA-repair proteins, and are associated with aggressive phenotype and poor patient outcomes (5–7). TGFβ is also implicated in resistance to chemotherapies for various cancers, including breast cancers (2). The mechanisms of TGFβ-mediated chemoresistance remain largely unknown. Those mechanisms appear to be diverse and depend on the cancer types, subtypes, stages, and the therapeutic regimens used during treatment (8–12), possibly as a result of the versatile and contextual properties of TGFβ signaling.

TGFβ can regulate gene transcription through the SMAD transcriptional factors that bind to promoters of target genes (13). More recently, TGFβ and SMADs have also been implicated in the regulation of microRNA (miRNA)
biogenesis. miRNAs are small regulatory RNAs that base-pair with the 3’ untranslated regions (UTR) of protein-encoding mRNAs, resulting in mRNA destabilization and/ or translational inhibition. Consistent with their extensive regulatory function, the biogenesis of miRNAs is tightly controlled, and dysregulation of miRNAs is linked to cancer (14, 15). Previous studies indicate that TGFb/SMADs regulate miRNA biogenesis at both the transcriptional and posttranscriptional levels. One of the posttranscriptional regulatory mechanisms involves binding of TGFb receptor–regulated SMADs to the stem region of primary miRNA transcripts (pri-miRNA) and to the Drosha/p68 miRNA-processing complex, possibly providing a platform to facilitate miRNA maturation (16, 17). From our previous studies, TGFb induces levels of both miR21 and miR181 families in breast cancer cells in a SMAD4-independent pattern via the interaction of SMAD2/3 with the Drosha complex (18, 19).

We reported that MSH2, coding for a central component of the DNA mismatch repair (MMR) machinery, is downregulated by TGFβ in breast cancer cells through miR21 (18). An inverse correlation between TGFβ1 and MSH2 expression is significant among primary breast cancers (18), suggesting the presence of this mechanism in vivo. MSH2 homolog 2 (MSH2) plays a key role in the recognition and repair of DNA replication errors, contributing to genomic integrity. In cancer cells, MSH2 identifies DNA adducts caused by many chemotherapeutic drugs and triggers further MMR-mediated signaling that results in cell-cycle arrest and apoptosis (20, 21). In another report, we found that TGFβ downregulates ATM in breast cancer cells by inducing the miR181 family, which targets the 3’UTR of ATM transcripts (19). Upon DNA damage, the ataxia telangiectasia–mutated (ATM) kinase phosphorylates key proteins in checkpoint control, such as P53, BRCA1, and CHEK2, resulting in cell-cycle arrest, DNA repair, or apoptosis (22). On the basis of the previous work, we focused on the effect of TGFβ on the DNA damage response and further identified BRCA1 as a target downregulated by the TGFβ/miR181 axis. Through this mechanism, TGFβ could sensitize TNBC cells to PARP inhibitors as demonstrated by our in vitro and in vivo models.

Materials and Methods

Cells, plasmids, and viruses

All cell lines were obtained from the ATCC and cultured in the recommended media in a humidified 5% CO2 incubator at 37°C. To generate MDA231–Alk5<sup>TD</sup>, MDA231–Alk5<sup>KR</sup>, and MDA231–vec, retroviruses encoding TBJRi<sup>Alk5</sup><sup><sup>T</sup>204D</sup>, Alk5<sup>K232R</sup> (3), or the empty pBMN-I–GFP vector were produced by transfecting Ampho-Phoenix cells and then used for transduction, followed by GFP selection. The miR181a/b and MSH2 expression plasmids were constructed and described elsewhere (18, 19). The BRCA1 expression construct was kindly provided by Dr. Jeffrey D. Parvin (Ohio State University, Columbus, Ohio). The ATM expression construct (23) was obtained from Addgene. Plasmid constructions and additional reagents are described in Supplementary Material. Cell transfection, reporter assays, production of viruses, as well as infection, and selection of transduced cells were carried out as previously described (19). Recombinant human TGFβ1 was purchased from R&D Systems. The type 1/II TGFβ receptor inhibitor LY2109761 was provided by Eli Lilly and Company. ABT-888 was purchased from Chemie-Tek. 4-Amino-1,8-naphthalimide (ANI), doxorubicin, methyl methanesulfonate (MMS), and 6-thioguanine (6-TG) were purchased from Sigma.

RNA extraction, RT-qPCR, and Western blot analysis

These procedures were performed as described previously (18, 19). Sequences of the primers can be found in Supplementary Material.

DNA-repair reporter assays

MDA-MB-231 cells with stable expression of I-SceI/GFP–based double-strand break (DSB) repair reporters (DR-GFP and EJ5-GFP; ref. 24) were generated by transfection and puromycin selection, and subsequently pretreated with TGFβ (5 ng/mL) for 20 hours before transfected with the I-SceI expression vector or a GFP expression vector (as a control for transfection efficiency) using Lipofectamine 2000 (Life Technologies). After 3 days of culture with continuous presence or absence of TGFβ, the percentage of GFP<sup>+</sup> cells was determined by FACS analysis using a Cyan ADP analyzer (Beckman Coulter). The percentage of GFP<sup>+</sup> cells in the I-SceI–transfected group was divided by the percentage of GFP<sup>+</sup> cells in the GFP–transfected group to obtain the frequency of the repair event marked by GFP<sup>+</sup>.

Immunofluorescence and comet assay (single-cell gel electrophoresis)

Immunofluorescence was performed using a γ-H2AX antibody (EMD Millipore) and a Cyclin A antibody (Abcam) as described previously (25). For comet assay, an OxiSelect comet assay kit (Cell Biolabs) was used under a neutral condition following the manufacturer’s protocol. Fluorescent images were captured using a Princeton Instruments cooled CCD digital camera from a Zeiss upright LSM 510 2-Photon confocal microscope. Olive tail moment was calculated using the formula tail DNA% × tail moment length.

HPRT mutation frequency analysis

Selection of HPRT<sup>+</sup> (hypoxanthine phosphoribosyltransferase) mutants was performed as described using cells that had been cleansed for preexisting HPRT<sup>−</sup> mutants (26, 27). Details can be found in Supplementary Material.

MTT (thiazolyl blue tetrazolium bromide) cell viability assay and calculation of coefficient of drug interaction

MTT assay was performed as described previously (18). Coefficient of drug interaction (CDI) was calculated using the formula AB/(A×B), in which AB represents the ratio of the cell viability in the combination group versus that in the
control group, whereas A and B represents the ratio of the cell viability in the single-agent group versus that in the control group. A CDI = 1 is defined as additive effect between agent A and B, CDI < 1 synergistic effect, CDI > 0.7 significantly synergistic effect, and CDI > 1 antagonistic effect.

Xenograft tumor model

All animal experiments were approved by the Institutional Animal Care and Use Committee at City of Hope. MDA231-vec or MDA231-Alk5TD cells (2 × 10⁶) were injected into the number 4 mammary fat pad of 6-week-old female NOD/SCID/IL2Rγ-null (NSG) mice. Doxorubicin (5 mg/kg) was administered weekly through i.p. injection and ABT-888 (50 mg/kg) daily via oral gavage, both starting at day 10 after cancer cell implantation. After tumors became palpable, tumor volume (mm³) was assessed by caliper measurements using the formula (width² × length)/2. At the end of the experiment, tumors were collected and dissociated tumor cells were subjected to 6-TG selection as described above and Western blot analysis.

In situ hybridization and immunohistochemistry

In situ hybridization (ISH) was performed using the miRCURY LNA microRNA ISH Optimization Kit (Exiqon). IHC staining was performed as previously reported (28). Details can be found in Supplementary Material.

Statistical analysis

For breast cancer dataset inquiry, six pooled breast cancer datasets of 947 primary tumors as well as an independent dataset of 295 primary breast cancers (29, 30) were analyzed by selecting 25% highest expressers and 25% lowest expressers of TGFB1 and comparing levels of the DNA-repair genes between the two groups. Kendall tau-b bivariate correlation analyses were used for the tissue array. Student t tests were used for comparison of means of quantitative data between groups. The statistical analyses were performed using SPSS 16.0 software package. Values of P < 0.05 were considered significant. All quantitative data are presented as mean ± SD.

Results

TGFB regulates the expression of DNA-repair genes in breast cancer cells

In this study, we focused on clinically aggressive, hard-to-treat TNBCs that often exhibit active TGFB signaling (3) and high expression of DNA-repair proteins (7). We further focused on the regulation of TGFB of the DNA-repair pathways as our previous studies indicate that TGFB downregulates MSH2 and ATM, two important DNA-repair genes, although these studies did not address the consequent effects of TGFB on DNA-repair function (18, 19). Treatment of MDA-MB-231 cells, a TNBC cell line, with exogenous TGFB resulted in >50% reduction of the RNA levels of MSH2, MSH6, MLH1, ATM, and BRCA1. These effects were completely abolished by LY2109761, a type I/II TGFB receptor (TBRI/II) inhibitor (Fig. 1A). Expression of a constitutively active mutant cDNA of TBRI (Alk5⁰⁴D, abbreviated to Alk5TD hereafter) largely recapitulated the regulation of these genes by TGFB (Fig. 1B). To test the role of receptor kinase activity, a kinase-dead TBRI cDNA (Alk5⁰⁴D, abbreviated to Alk5KR hereafter) was expressed in MDA-MB-231. In those cells producing Alk5KR, the expression levels of all the DNA repair or response genes were greater than the vector only cells (Fig. 1B). Similar results were observed in another TNBC line MDA-MB-468 when treated with TGFB (Fig. 1C). At the protein level, only ATM, MSH2, and BRCA1 consistently exhibited significantly lower levels when treated with TGFB ligand or expression of Alk5TD in both TNBC lines (Fig. 1D and data not shown). We therefore focused on ATM, MSH2, and BRCA1 in the subsequent studies for their potential role in mediating the effects of TGFB on DNA repair. We also tested two luminal breast cancer lines BT474 and MCF7. Although TGFB caused significant downregulation of BRCA1 and modest downregulation of MSH2 and ATM in BT474 cells, its effect on the DNA-repair genes was negligible in MCF7 cells treated under the same experimental conditions (Supplementary Fig. S1A and S1B).

To obtain further evidence for the regulation of TGFB of these DNA-repair genes, we analyzed six pooled breast cancer datasets of 947 primary tumors (NKI947) as well as an independent dataset of 295 primary breast cancers (NKI295; refs. 29, 30). In the analyses of either the pooled or independent datasets, in the breast cancers that were the 25% highest TGFB1 expressers, significantly lower levels of BRCA1 and MSH2 transcripts were present, compared with the breast cancers that were the 25% lowest TGFB1 expressers (Fig. 1E and F). The association between expression of TGFB1 and ATM, however, was not significant (data not shown). Nevertheless, the results showing inverse correlations of BRCA1 and MSH2 with TGFB1 levels are consistent with our in vitro data, indicating that TGFB1 downregulates these genes (Fig. 1A–D).

TGFB induces a DNA-repair deficiency in breast cancer cells

To assess the effect of TGFB signaling on DNA repair, we first used previously described DSB reporters for homology-directed repair (HDR) and end joining (EJ): DR-GFP and EJ3-GFP, respectively (24). The results indicated that pretreatment with TGFB significantly reduced HDR in MDA-MB-231 cells without affecting the frequency of EJ (Fig. 2A). We then examined formation of γ-H2AX foci in MDA-MB-231 cells with or without pretreatment with TGFB. Following ionizing radiation (IR), cells with both γ-H2AX foci and expression of Cyclin A, an S/G2-phase marker, were counted. TGFB treatment significantly reduced γ-H2AX foci formation in Cyclin A+ cells upon DNA damage (Fig. 2B), consistent with its ability to downregulate ATM (Fig. 1A–D). We next performed comet assays to evaluate levels of DNA damage after treatment with the genotoxic chemotherapeutic agent doxorubicin. MDA-MB-231 cells expressing Alk5TD constantly carried higher levels of DNA damage compared with cells expressing Alk5KR or the control vector.
as demonstrated by an increase in olive tail moment that was observed at 6 hours after drug exposure and persisted at 24 hours (Fig. 2C). Overexpression of ATM, MSH2, or BRCA1 cDNAs all partially reduced the DNA-damage levels, with BRCA1 exhibiting the most significant effect (Fig. 2D). These results indicate that TGFβ induces a DNA-repair deficiency in TNBC cells through downregulating DNA-repair genes.

**TGFβ induces a genomic instability through regulating DNA repair**

Because DNA-repair function is tightly related to genomic stability, we further analyzed mutation frequencies at the *HPRT* gene in cells undergoing active TGFβ signaling as a means to assess the mutagenic potential of TGFβ-induced DNA-repair deficiency. MDA-MB-231 cells treated with TGFβ or expressing Alk5**TD** cDNA but not Alk5**KR** exhibited significantly higher spontaneous mutation frequency than the control cells (Fig. 3A and B). Upon treatment with DNA-damaging agents MMS and doxorubicin, the drug-induced mutation frequencies were approximately 3- to 8-fold higher when cells expressed Alk5**TD** cDNA (Fig. 3C). Again, overexpression of ATM, MSH2, or BRCA1 cDNA partially reduced the spontaneous and doxorubicin-induced mutation frequencies, with BRCA1 exhibiting the strongest...
effect (Fig. 3D). Thus, the downregulation of these DNA-repair genes by TGFβ is associated with increased mutation frequency and genomic instability.

Another consequence of TGFβ-mediated cosuppression of ATM, MSH2, and BRCA1 in TNBC cells is a dependence of cancer cells on the base excision repair pathway. PARP has roles in the base excision repair pathway, and also participates in other cellular processes. BRCA or ATM deficiency induces cancer sensitivity to PARP inhibition (31–34). As a synthetic lethal approach, PARP inhibitors have shown promising effects for BRCA-mutated breast cancers as well as TNBCs (31, 35). To determine whether TGFβ simulates a “BRCAness” phenotype by inducing sensitivity to PARP inhibition, we examined the BRCA-proficient MDA-MB-231 and MDA-MB-468 TNBC cells...
undergoing active or suppressed TGFβ signaling. Treatment with TGFβ or expression of Alk5TD induced the sensitivity to PARP inhibition by ANI or ABT-888. Inhibition of TGFβ signaling by LY2109761 resulted in reduced sensitivity to PARP inhibition, and completely abolished the effect of TGFβ (Fig. 4A). To dissect the role of ATM, MSH2, and BRCA1 in mediating this effect, specific siRNAs were used to knockdown the expression of those genes either singularly or in combination (Fig. 4B). Among the single-gene knockdowns, knockdown of BRCA1 was most effective in inducing sensitivity to PARP inhibition to a level that was comparable with that induced by ATM and MSH2 double knockdown, whereas knockdown of all three genes conferred cells the highest sensitivity to ABT-888 (Fig. 4C). In contrast, overexpression of any single cDNA of ATM, MSH2, or BRCA1 in Alk5TD-expressing cells completely abolished the TGFβ-induced sensitivity to ABT-888 (Fig. 4D and E). Consistent with its ability to downregulate DNA-repair genes, TGFβ was able to sensitize BT474 cells, but not MCF7 cells in which it fails to regulate DNA-repair genes, to PARP inhibition by ABT-888 (Supplementary Fig. S1C and S1D).

PARP inhibition overcomes TGFβ-mediated insensitivity to doxorubicin in vitro and in vivo

Previous results from our and other groups indicate that TGFβ induces a resistance to conventional chemotherapy drugs through various mechanisms and TGFβ inhibition enhances chemotherapy action in TNBCs (2, 8–12, 18). We therefore examined whether PARP inhibition in TNBC cells undergoing active TGFβ signaling could overcome TGFβ-mediated chemoresistance and thus might enhance the efficacy of conventional chemotherapy in these tumors. Activation of TGFβ signaling by TGFβ treatment or expression of Alk5TD induced a significant resistance to doxorubicin in MDA-MB-231 cells (Fig. 5A and B). Addition of ABT-888 to doxorubicin treatment overcame the resistance to the latter in Alk5TD-expressing cells (Fig. 5C), and induced a significant synergy between the two drugs at all tested concentrations in MDA-MB-231 undergoing active TGFβ signaling (Fig. 5D).

To further examine this TGFβ effect in vivo, we established orthotopic xenograft tumors in NSG immunocompromised mice by injecting MDA-MB-231 cells expressing Alk5TD or the control vector into the mammary fat pad. ABT-888 or PBS was administered daily starting at day 10 after cancer cell implantation. The Alk5TD-expressing tumors, but not the control tumors, responded to single-agent ABT-888 treatment, as demonstrated by significantly reduced tumor volumes (Fig. 5E). In another experiment, we compared the effect of doxorubicin single-agent treatment and the combination of doxorubicin and ABT-888 in the two types of xenograft tumors with or without TGFβ activation. The MDA-MB-231 control tumors exhibited a clear response to doxorubicin; addition of ABT-888 had no further effect on tumor growth. In contrast, the Alk5TD-expressing tumors did not show a significant reduction in tumor volume upon doxorubicin treatment, but exhibited a significant response to the combination of doxorubicin and ABT-888 (Fig. 5F).
We further determined the mutation frequency in dissociated tumor cells collected from PBS- or doxorubicin-treated mice and found that the Alk5TD-expressing tumors exhibited increased genomic instability as demonstrated by increased spontaneous and drug-induced mutation frequencies, compared with the control tumors without TGFβ activation (Fig. 5G). Levels of γ-H2AX were also lower in Alk5TD-expressing tumors receiving PBS or doxorubicin (Fig. 5H), suggesting impaired DNA-repair function and/or reduced cell death in these tumors. Overall, the in vitro and in vivo data demonstrate that TNBC cells with active TGFβ signaling are more resistant to doxorubicin but more sensitive to PARP inhibition and suggest that single-agent treatment with ABT-888 or in combination with conventional chemotherapy would be effective against sporadic TNBCs exhibiting TGFβ activation.

**TGFβ downregulates BRCA1 through miR181**

We previously reported the miRNA-mediated mechanisms for the downregulation of ATM and MSH2 by TGFβ (18, 19); however, the mechanism of TGFβ downregulation of BRCA1, which was the major mediator of many effects described above, remained unknown. In a search for the potential mechanisms regulating BRCA1 expression, we scanned the 3'UTR of BRCA1 and found a putative binding site for the miR181 family (miR181a/b/c/d sharing the same seed sequence), which we have previously reported to be unregulated by TGFβ at the posttranscriptional level in breast cancer cells (Fig. 6A; ref. 19). We then cloned the putative miR181-binding region in the BRCA1 3'UTR, either in the wild-type or with the miR181-recognition sequence mutated, downstream to a Renilla luciferase reporter.
reporter gene in the psiCHECK vector. MDA-MB-231 cells were transfected with the reporter constructs together with a miR181a/b-expressing plasmid or vector. The reporter construct carrying wild-type miR181–binding site but not the mutated site exhibited significant inhibition by miR181a/b (Fig. 6B). Consistently, overexpression of miR181a/b that also targets ATM (19), but not miR21 that targets MSH2 (18, 36), resulted in downregulation of BRCA1 protein levels in both MDA-MB-231 and MDA-MB-468 TNBC cells (Fig. 6C). To further confirm that miR181 mediates the effect of TGFβ on downregulating BRCA1 expression, MDA-MD-231 and MDA-MB-468 cells were transfected with anti-miRNAs before being treated with TGFβ. Inhibition of miR181, but not miR21, increased BRCA1 expression and abolished the downregulation of TGFβ at the protein level (Fig. 6D and F). When cells transfected with
anti-miRNAs were examined for their responsiveness to ABT-888, anti-miR181 exhibited a greater effect on suppressing TGFβ-induced sensitivity comparing with anti-miR21, whereas coinhibition of miR181 and miR21 most effectively abolished the effect of TGFβ (Fig. 6E and G). These results are consistent with the previous observations that all three TGFβ-targeted DNA-repair genes, that is, ATM, MSH2, and BRCA1, individually regulated by miR181 (for ATM and BRCA1) and miR21 (for MSH2), contribute to TGFβ-induced sensitivity to PARP inhibition (Fig. 4B–E).

TGFβ is associated with miR181 and BRCA1 levels as well as disease progression in primary TNBCs

To extend the herein identified mechanism to primary tumors, a tissue array, including 48 cases of TNBCs, was used to evaluate the levels of TGFβ1, miR181, and BRCA1. Significant positive correlation was detected between TGFβ1 and miR181 (Tau-b = 0.638, P < 0.001), whereas significant inverse correlations were detected between TGFβ1 and BRCA1 (Tau-b = −0.525, P < 0.001) and between miR181 and BRCA1 (Tau-b = −0.477, P < 0.001). In addition, higher levels of TGFβ1 and miR181 and lower levels of BRCA1 were also significantly associated with higher clinical grades and stages (Fig. 7A–D).

Discussion

As one of the first clinical applications of synthetic lethality-based cancer therapeutics, PARP inhibition selective for BRCA1/2 deficiency has shown promising effect for the treatment of patients with tumors bearing BRCA1/2 mutations (34, 37). As hereditary cancers with BRCA1/2 mutations only account for about 5% to 10% of breast cancers (38) and 15% of ovarian cancers overall (39), characterizing tumors with wild-type BRCA1/2 genes but also sensitive to PARP inhibitors is of great clinical interest. Recent studies suggest...
that PARP inhibitors are promising agents for the treatment of TNBCs, which share similar gene-expression profiles and DNA-repair deficiencies with BRCA1-associated breast cancers (35, 40). Cells that manifest several recently reported epigenetic silencing mechanisms of BRCA1/2 expression show enhanced sensitivity to PARP inhibition. These include hypermethylation of BRCA1 CpG island (41), miRNA-mediated downregulation of BRCA1 (42–44), and depletion of mitochondrial DNA leading to upregulation of miR1245 and the ubiquitin ligase Skp2 that, respectively, suppress BRCA2 protein translation and stability (45). Interestingly, patients with ovarian cancer carrying BRCA1/2 mutations have better overall survival than BRCA1/2 wild-type cases, whereas the survival for epigenetically silenced BRCA1 cases was similar to BRCA1/2 wild-type cases, suggesting that patient survival depends on the mechanism of BRCA gene inactivation (46). Genomic alterations of other genes that may affect the sensitivity of cancer cells to PARP inhibitors, including the homologous recombination genes ATM and CHEK2 whose mutations have been associated with risk of breast cancers (7, 47) and PTEN, have been reported in breast and ovarian cancers (46, 48). In addition, inhibition of cyclin-dependent kinase 1 (CDK1), a kinase that phosphorylates BRCA1 and is, therefore, necessary for BRCA1-mediated functions, has been reported to sensitize MDA-MB-231 cells to PARP inhibition (49). Interestingly, a recent study shows that PARP-1 interacts with multiple MMR proteins and may regulate or participate in MMR (50). On the other hand, MSH2 has been shown to promote HDR (51). It is, therefore, possible that reduced expression of MSH2 results in a partial

Figure 7. TGFβ is associated with miR181 and BRCA1 levels as well as disease progression in primary TNBCs. A, representative images of ISH and IHC staining in primary TNBCs; bar, 100 μm. B to D, levels of TGFβ1, miR181, and BRCA1 were determined by IHC or ISH in a TNBC tissue array (n = 48) and scored as described in Materials and Methods. Correlation analyses were carried out among their expression levels (B) and for each of them with clinical grades (C) or stages (D). Kendall Tau-b coefficient, R square linear, and P values are shown. Clinical stages are scored as: 0, stage 0; 1, stage I; 2, stage II; 3, stage III; 4, stage III; 5, stage IV; and 6, stage IV.
dependence on PARP-1 for DNA repair, which may explain the slightly enhanced sensitivity to PARP inhibition in cells with MSH2 knockdown (Fig. 4C).

Here, we show that TGFβ, a multitasking cytokine frequently elevated in tumor microenvironments, regulates DNA repair by simultaneously suppressing the expression of ATM, MSH2, and BRCA1. This results in a BRCA1-like phenotype, including impaired DNA-repair efficiency and reduced genomic stability, as well as a synthetic lethality to PARP inhibition. Our in vitro and in vivo data demonstrate that PARP inhibitors, such as ABT-888, which is under clinical trials for breast cancers, may have a more potent effect on those TNBCs with active TGFβ signaling. This may allow selection of appropriate patients with TNBC based on markers of TGFβ pathway (e.g., TGFβ and phosphorylated SMAD2/3) for PARP-targeting therapy. In addition, other factors that induce the level or activity of miR181 and/or miR21 may also affect the expression of the target genes of the miRNA, including ATM, MSH2, or BRCA1, and therefore may affect tumor response to PARP inhibitors. In fact, a recent study demonstrates that miR181a/b levels inversely correlate with ATM in breast cancers and determine the sensitivity of TNBC cells to PARP1 inhibition (52). Those factors regulating miR181 and miR21 may, therefore, also have values as prognostic markers for PARP-targeted therapy in sporadic breast cancers. Although our focus for this study is on clinically aggressive, hard-to-treat TNBCs that often exhibit active TGFβ signaling, the pathways identified herein may have a general application to understanding cancer and defining treatments.

TGFβ has been implicated in chemoresistance through a variety of mechanisms (2, 8–12, 18). Relevant to the study herein, downregulation of MSH2 and ATM, which serve as sensors of DNA damage upon genotoxic treatment, may contribute to TGFβ-induced resistance to DNA-damaging agents such as doxorubicin (Fig. 5C and F). It is well documented that the inability of MMR-deficient cells to recognize chemotherapy-induced DNA-damage results in a damage-tolerant phenotype and drug resistance (53). In colorectal cancer cells, MSH2 downregulation by miR21 significantly reduces 5-fluorouracil (5-FU)–induced cell-cycle arrest and apoptosis (36). ATM has a master role in triggering DNA repair upon DSBs, as evidenced by the hypersensitivity of cells from ataxia telangiectasia patients to IR (54), but there is a discrepancy of ATM deletion/suppression on cancer response to DNA-damaging therapies. A recent study revealed a mechanism for the binary effect of loss of ATM on therapeutic response. In P53-deficient tumors, suppression of ATM sensitizes cells to DNA-damaging chemotherapy, whereas in the presence of functional P53, suppression of ATM or CHEK2 protects cells from genotoxic agents by blocking P53-dependent apoptosis (55).

In addition, regulation of the DNA-repair genes by TGFβ is dependent on the cellular context. In noncancerous cells, we observe an opposite inductive effect of TGFβ on MSH2 expression as a result of SMAD-mediated, P53-dependent promoter activation, which is absent due to P53 deficiency or overcome by miR21-mediated downregulation of MSH2 in cancer cells (18). TGFβ downregulates BRCA1, MSH2, and ATM and induces sensitivity to PARP inhibition in MDA-MB-231 and MDA-MB-468 TNBC cells and in BT474 luminal breast cancer cells, but not in MCF7 luminal breast cancer cells (Supplementary Fig. S1). Therefore, the ultimate effects of TGFβ on different DNA-repair pathways and, consequently, on cell response to different types of DNA damage are likely to be context-dependent. A comprehensive assessment of these contextual factors (e.g., P53 status) and the status of various DNA-repair pathways, along with assessment of TGFβ signaling, will likely provide valuable prognostic information leading to individualized treatment of breast cancers.

Disclosure of Potential Conflicts of Interest
George Somlo is a consultant/advisory board member for Novartis, Celgene, Pfizer, and Quest. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Liu, W. Zhou, C.-T. Cheng, G. Somlo, M.Y. Fong, A.R. Chin, Y. Yu, S.T.F. O’Connor
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C.-T. Cheng, M.Y. Fong, Y. Yu, J.M. Stark, S.E. Wang
Writing, review, and/or revision of the manuscript: L. Liu, C.-T. Cheng, G. Somlo, M.Y. Fong, S.T.F. O’Connor, T.R. O’Connor, J.M. Stark, S.E. Wang
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): W. Zhou, Y. Yu, Y. Xu, S.T.F. O’Connor, S.E. Wang
Study supervision: S.E. Wang

Acknowledgments
The authors thank both Dr. John J. Rossi (City of Hope) for kindly providing the pFU1 expression plasmid and Dr. Jeffrey D. Parvin (Ohio State University) for the BRCA1 expression plasmid. The authors also thank Des. Binhui Shen, Susan Kane, and Shihua Chen for valuable comments, as well as the City of Hope Core Facilities for highly professional services.

Grant Support
This work was supported by NIH grants R01CA163586 and R01CA166020 (to S.E. Wang), R01CA120954 (to J.M. Stark), R01CA176611 (to J. Termini and T.R. O’Connor), R01DE14183 and R01DE10742 (to D.K. Ann), and P30CA035722, and by National Natural Science Foundation of China grant 81171983 (to H. Li) and 81201725 (to Y. Yu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 15, 2014; revised July 9, 2014; accepted July 27, 2014; published OnlineFirst August 7, 2014.

References
15. Liu et al. Mol Cancer Res; 2014

Published OnlineFirst August 7, 2014; DOI: 10.1158/1541-7786.MCR-14-0201

Downloaded from mcr.aacrjournals.org on October 27, 2017. © 2014 American Association for Cancer Research.


Molecular Cancer Research

TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes

Liang Liu, Weiying Zhou, Chun-Ting Cheng, et al.

Mol Cancer Res  Published OnlineFirst August 7, 2014.

Updated version Access the most recent version of this article at: doi:10.1158/1541-7786.MCR-14-0201

Supplementary Material Access the most recent supplemental material at: http://mcr.aacrjournals.org/content/suppl/2014/08/16/1541-7786.MCR-14-0201.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.